References
- AntoniniAAbbruzzeseGBaronePCOMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor featuresNeuropsychiatr Dis Treat2008419
- BirkmayerWHorneykiewiczOThe effect of 3,4-dihydroxyphenylalanine (=DOPA) on Parkinsonian akinesiaWien Klin Wochenschr196173787813869404 Republished in English in Parkinsonism Relat Disord, 1998, 4:59–60.18591089
- BrooksDJOptimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspectiveNeuropsychiatr Dis Treat200843947
- DorseyERConstantinescuRThompsonJPProjected number of people with Parkinson’s disease in the most populous nations, 2005 through 2030Neurology200768384617082464
- FrisinaPGBorodJCFoldiNSDepression in Parkinson’s disease: Health risks, etiology, and treatment optionsNeuropsychiatr Dis Treat200845969
- KatzenschlagerRAnticholinergics for symptomatic management of Parkinson’s diseaseCochrane Database Syst Rev20072CD00373512804486
- LeeKCChenJJTransdermal selegiline for the treatment of major depressive disorderNeuropsychiatr Dis Treat2007252737
- LooiJCLMatiasMRuzichMJConceptualization of depression in Parkinson’s diseaseNeuropsychiatr Dis Treat200521354318568058
- LundqvistCContinuous levodopa for advanced Parkinson’s diseaseNeuropsychiatr Dis Treat2007333548
- NayaklHenchcliffeCRasagiline in treatment of Parkinson’s diseaseNeuropsychiatr Dis Treat200841120
- PinderRMPathological gambling and dopamine agonists: A phenotype?Neuropsychiatr Dis Treat2007312
- [WHO/WFN] World Health Organisation/World Federation of NeurologyAtlas. Country Resources for Neurological Disorders2004GenevaWHO